Dr. Todd McAllister, Ph.D. – Co-Founder and CEO of Cytograft Tissue Engineering
Dr. McAllister received his Ph.D. in BioMedical Engineering from the University of California, San Diego. He is the co-founder and CEO of Cytograft Tissue Engineering, Inc. Dr. McAllister has been an early proponent of biological approaches to tissue engineering that do not require synthetic scaffolds. Dr. McAllister has also pioneered a novel business strategy within Regenerative Medicine, taking Cytograft’s lead product, the Lifeline™ Vascular Graft from inception to commercial licensure in Europe on less than $10M in private equity.
Dr. McAllister also served as Co-Director of the Center for Regenerative Medicine at the St. Joseph’s Translational Research Institute in Atlanta, where he oversaw a broader range of cell-based cardiovascular repair technologies. He also serves on several advisory boards, including Lumen, Biocardia, and the Medical University of South Carolina.
Dr. Nicolas L’Heureux, Ph.D. – Co-Founder and CSO of Cytograft Tissue Engineering
Dr. L’Heureux received his Ph.D. in Cell Biology from Laval University in Quebec, Canada and was a post-doctoral AHA fellow in the Department of Bioengineering at the University of California, San Diego. He is the co-founder and CSO of Cytograft Tissue Engineering, Inc. Dr. L’Heureux invented Tissue Engineering by Self-Assembly (TESA), a novel tissue engineering strategy. He advocates a biological approach to Regenerative Medicine, minimizing the inclusion of synthetic scaffolds and exogenous biomaterials.
Dr. L’Heureux also served as Co-Director of the Center for Regenerative Medicine at the St. Joseph’s Translational Research Institute in Atlanta. As a co-director he oversaw research of cell-based cardiovascular repair technologies.
Dr. Nathalie Dusserre, Ph.D. – Vice President of Manufacturing and Regulatory Affairs of Cytograft Tissue Engineering
Dr. Dusserre received her Ph.D. in Cell Biology and Microbiology from Claude Bernard University in Lyon, France. She was a post-doctoral fellow at the Infectious Diseases Research Center at Laval University in Quebec Canada and a postgraduate researcher in the Department of Bioengineering at the University of California, San Diego.
As the Vice President of Manufacturing and Regulatory Affairs at Cytograft Tissue Engineering, Dr. Dusserre oversees all regulatory aspects of Cytograft’s operations. Under her leadership, Cytograft has successfully acquired commercial licensure in Germany and clinical licensure in Poland, Slovakia and the United Kingdom. She is also currently leading interactions with the FDA regarding the recent submission of an IND application for LifeLine™. In addition to her regulatory role, Dr. Dusserre also manages Cytograft’s manufacturing and research teams.
May 20, 2014 – Dr. L’Heureux to be the keynote speaker at the French National Meeting on Biomaterials Research (“Assises Nationales de la Recherche en Biomatériaux”; Autrans, France).
May 5, 2014 – Dr. McAllister to present Cytograft’s unique and successful business model at the Regenerative Medicine conference in San Francisco. Program details can be found here.
April 27, 2014 – Dr. L’Heureux to present recent results regarding the use of “Cell-synthesized extracellular matrix particles for tissue engineering and aesthetic applications” at the Experimental Biology 2014 meeting in San Diego. Link to the published abstract in the FASEB Journal here.
April 25, 2014 – Dr. McAllister to present on the convergence of tissue engineering and bioprinting at the ISCT annual meeting. Meeting agenda is here.
March 16, 2014 – Dr. McAllister publishes a perspective manuscript in MedNous. Full text is available here.
March 14, 2014 – A patent application describing the new abdominal aorta aneurism (AAA) repair device created by Cytograft is published by the USPTO (Patent application 20140081385)
March 14, 2014 – Dr. L’Heureux to speak at the INSERM Workshop #226 “3D cell culture bridges the gap between cell culture and live tissue” (Bordeaux, France).
March 14, 2014 – Dr. McAllister presents data in an invited lecture at the Ohio State University wound Care Conference. Conference program can be found here.
October 28, 2013 – Dr. L’Heureux to hold a seminar at the Vascular Surgery Institute of Fudan University Medical School (Shanghai, China).
October 7, 2013 – Results from the “First human use of an allogeneic tissue-engineered vascular graft for hemodialysis access” are published in the Journal of Vascular Surgery (available as Epub ahead of print). Link to publisher here.
December 5, 2013 – Drs. L’Heureux and McAllister publish in the 2012 World Stem Cell Report. In this invited manuscript, Cytograft’s founders propose revised regulatory standards for autologous cell therapies. See the full length manuscript in Regenerative Medicine here.